Next Article in Journal
Anti-Aging, Anti-Acne, and Cytotoxic Activities of Houttuynia cordata Extracts and Phytochemicals Analysis by LC-MS/MS
Next Article in Special Issue
Case Reports and Experts Opinions about Current Use of Leech Therapy in Dermatology and Cosmetology
Previous Article in Journal / Special Issue
Total Phenolic Content, Antioxidant Capacity and UV Radiation Protection Properties of Marigold (Calendula officinalis), Carrot (Daucus carota), Tomato (Solanum lycopersicum) and Hop (Humulus lupulus) Extracts
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cosmetics
Volume 9
Issue 6
10.3390/cosmetics9060135
cosmetics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Evaluation of Tolerance and Trichological Efficacy of a Food Supplement in Men and Women with Telogen Effluvium-like Disorder

by
Fabio Rinaldi
,
Barbara Marzani
and
Daniela Pinto
*
Human Microbiome Advanced Project, HMAP, 20129 Milan, Italy
*
Author to whom correspondence should be addressed.
Cosmetics 2022, 9(6), 135; https://doi.org/10.3390/cosmetics9060135
Submission received: 18 October 2022 / Revised: 1 December 2022 / Accepted: 2 December 2022 / Published: 7 December 2022
(This article belongs to the Special Issue Feature Papers in Cosmetics in 2022)
Browse Figure
Review Reports Versions Notes

Abstract

:
Hair thinning is a very common problem in dermatology, affecting both men and women, and can strongly impact the quality of life of subjects. In this view, therapies that aim to reduce the appearance of thinning by delaying, arresting, or reversing the course of hair thinning are highly desirable. A novel nutraceutical product (NS) containing active botanicals, a patented composition comprising rutin and polyunsaturated fatty acids (PUFAs), zinc, biotin, and ornithine, has been developed to improve hair growth in subjects with hair thinning. Sixty subjects with telogen effluvium-like hair loss were randomized 1:1 in two groups (NS vs. placebo) and treated for three months and evaluated at the baseline visit (T0), and after 15 days (T1) and one (T2), two (T3), and three (T4) months of treatment. Two follow-up visits one month (T5) and two months after the last assumption (T6) were also included in the protocol. Subjects were evaluated for the percentage of hair in the anagen phase, density of hair in the anagen phase (n/cm2), vellus hair (miniaturized, smaller, and thinner hair), and the entity of hair loss in the telogen phase (pull test). NS supplementation produced a statistically significant (p < 0.05) increase in anagen hair and hair density versus baseline from 15 days (T1) of treatment and this effect was not detectable for placebo. Moreover, a clinically/statistically significant (p < 0.05) decrease in vellus hair was also reported, suggesting not only a rapid reduction of the process of miniaturization of the hair but also a transformation of vellus hair into terminal hair. The NS treatment also showed a significant (p < 0.05) increase in tensile strength till T6 (vs. placebo). A higher percentage of subjects who took the NS noted a reduction in daily hair loss, an increase in brightness, and the presence of stronger hair. No side effects were reported. The present study confirms the clinical efficacy and safety of novel nutraceutical supplements in men and women with hair thinning, acting as a multi-targeted therapeutic approach to hair thinning due to TE-like phenomena.

1. Introduction

Hair loss or hair thinning is a common complaint in clinical dermatology. Hair loss can be classified according to cause and presentation [1]. The four common hair loss disorders that occur in both men and women are androgenetic alopecia (AGA), telogen effluvium (TE), alopecia areata (AA), and scarring alopecia [1].
Hair thinning has to be considered as an accumulation of multiple factors strictly linked to the complex biology of the hair follicle (HF) [2]. These factors include hormone unbalancing, genetics, diet, stress, oxidative damage, and ageing but also extrinsic factors such as ultraviolet radiation and pollution [2]. The combination of two or more of these factors leads to the dysregulation of physiological hair growth with the shortening of the anagen phase and the production of smaller, thinner, and less visible hairs.
Despite its relatively benign behaviour, hair thinning can cause feelings of poor self-image, low self-esteem, anxiety, and depression [3,4], with a consequent negative impact on the quality of life of subjects [5]. In this view, therapies aiming to reduce the appearance of thinning by delaying, arresting, or reversing the course of hair thinning are highly desirable.
A ground-breaking nutraceutical supplement (NS) has been developed to approach thinning in men and women (Bioscalin® NOVA•Genina). The supplement is a mixture of phyto-compounds (Ganoderma lucidum, Linum usitatissimum L., Cynara scolymus L., and Galeopsis segetum Neck.) with clinically proven dihydrotestosterone (DHT)-inhibiting and antioxidant properties [6,7,8,9,10,11,12]. It also contains polyunsaturated fatty acids (PUFAs), rutin, zinc, biotin, and ornithine with well-established efficacy on normal hair growth [13,14,15,16,17]. Indeed, nutritional deficiencies of minerals, essential fatty acids, amino acids, and vitamins are considered some of the major factors influencing hair loss [18,19].

2. Materials and Methods

2.1. Subjects

A total of 60 subjects were enrolled in this monocentric randomized double-blinded placebo-controlled study with 2 arms of 2 parallel groups (1:1/1:1 each). The study was conducted under the approval of the Ethical Independent Committee for clinical, not pharmacological, investigation in Genoa (Italy) and following the ethical standards of the 1964 Declaration of Helsinki.

2.2. Inclusion and Exclusion Criteria

Before inclusion, subjects were asked to sign an informed consent form indicating that they are aware of the investigational nature of the study.
Participants in the study were healthy male and female subjects aged 18–65 with telogen effluvium-like hair loss and a percentage of anagen ratio at inclusion < 75%, accepting to not receive any drugs/cosmetic treatments able to interfere with the study results, and no participation in a similar study at the time or during the previous 6 months.
Exclusion criteria included: pregnancy and lactation (for female subjects); subjects not in menopause who did not use adequate contraceptive precautions to avoid pregnancies during the study; sensitivity to any compound of the investigational product; the presence of cutaneous disease in the tested area such as lesions scars, or malformations; a self-reported history of diseases such as diabetes, endocrine disease, hepatic, renal, cardiac, or pulmonary disorders, cancer, neurological or psychological diseases, inflammatory/immunosuppressive diseases, or drug allergy.

2.3. Test Product

Subjects were randomized to receive the study product (Bioscalin® NOVA•Genina, Giuliani Spa, Milan, Italy) or a placebo. The novel oral NS contains Ganoderma lucidum, Linum usitatissimum L., Cynara scolymus L., and Galeopsis segetum Neck., a patented composition comprising rutin and PUFAs, zinc, biotin, and ornithine. Placebo treatment consisted of inert tablets with the same excipients and appearance.
Subjects were asked to ingest their assigned treatment once daily immediately following breakfast.

2.4. Study Evaluations

Evaluations were performed at the baseline visit (T0), and after 15 days (T1) and one (T2), two (T3), and three (T4) months of treatment. Two follow-up visits one month (T5) and two months after the last assumption (T6) were also included in the protocol. The clinical efficacy of the products under study was evaluated by the TrichoScan® software (Trichology GmbH, Freiburg, Germany) to define the percentage of hair in the anagen phase (number of HFs in the anagen phase), the anagen hair density, and the percentage of vellus hair. The evaluation of the entity of hair loss in the telogen phase was also carried out through a pull test.
Each subject was asked to fill out a questionnaire regarding the perception of hair growth improvement (0–10 scale) at T1, T2, T3, T4, and T5, the efficacy of the study treatment on hair volume and hair shine (4-point scale for intense improvement, mild improvement, no effect, or worsening at T1, T2, T3, T4, and T5), and the product tolerance (score: bad, poor, medium, good, excellent) at T4. Moreover, during the treatment phase, volunteers’ compliance was verified, while the possible events which could have interfered with the test results were evaluated at each study visit.

2.5. Study Endpoints

The primary endpoints were the increase in the percentage of hair in the anagen phase (active hair growth phase), the density of hair in the anagen phase (n/cm2), and vellus hair (miniaturized, smaller, and thinner hair). The secondary endpoints were the evaluation of the entity of hair loss in the telogen phase (pull test) and responses to the subject self-assessment questionnaire. Safety endpoints were potential adverse events (AEs).

2.6. Statistical Analysis

The activity of the food supplementation was expressed in absolute values versus baseline (evaluation of tested product vs. T0) and in comparison to each other. Clinical data were compared as results at each visit versus basal conditions using the Friedman test followed, in case of a statistically significant result, by a Holm–Sidak adjusted test. Instrumental data were analyzed using a non-parametric test (Friedman test) when the normality hypothesis was rejected by the Shapiro–Wilk normality test (threshold at 5%) or a parametric test (ANOVA test for repeated measures) when the normality hypothesis was confirmed, followed in case of a statistically significant result by a Holm–Sidak adjusted test.
p-values less than 0.05 were considered clinically significant.

3. Results

3.1. Demographic and Baseline Characteristics

The study was conducted on a total of 60 healthy subjects (33 females and 27 males), the age range of 18–65 years (mean = 44.33 ± 12.30), with telogen effluvium-like hair loss and a percentage of anagen ratio at inclusion <75%, whose informed consent had been obtained. The general characteristics of the study population (age, sex, treatment arm) are shown in Table 1.
Demographic and baseline characteristics were not significantly different between the two groups.
One “drop-out” occurred during the study in the placebo group because of personal reasons not related to the tested product’s use. No important side effects which may have interfered with the test results occurred; subjects’ compliance was >95% for all subjects who completed the first 3 months of the study (treatment phase).

3.2. Primary Endpoints

A phototrichogram (TrichoScan®) was performed on the frontoparietal area of the head. A scalp area of about 1 cm2 was shaven and a picture was taken. Thanks to a special template, which adapted to the cranial shape of each volunteer, the same scalp areas were identified at T0 and then after 15 days (T1), and one (T2), two (T3), and three (T4) months of treatment, one month after the last assumption (T5) and two months after the last assumption (T6). The microscopic images with 20× magnification were captured with FotoFinder Dermoscope (FotoFinder Italia s.r.l., Campi Bisenzio (FI), Italy).
The variation percentages (mean value) of anagen hair at each visit versus T0 are summarized in Table 2. A statistically significant (p < 0.05) difference between the NS and placebo was highlighted from T1 to T6. In particular, for NS a statistically significant (p < 0.05) increase in anagen hair versus baseline was reported (Table 2) after 15 days (T1) of treatment and this effect was not detectable for placebo.
Hair density was already statistically increased at T1 in the subjects treated with the NS (Holm–Sidak adjusted tests p < 0.05 T1, T2, T3, T4, T5 and T6 vs. T0) (Table 2), compared to placebo; the trophic effect of NS was still present 2 months after the last assumption (T6) (Holm–Sidak adjusted tests p < 0.05 T6 vs. T0) (Table 2). For the placebo group, no statistically significant variation versus baseline, at any study time, was observed (Table 2).
Moreover, the clinically/statistically significant (p < 0.05) decrease in vellus hair, more marked at T3 and T3 (Table 2) for the NS treatment (Holm–Sidak adjusted tests p < 0.05 T1 and T2 vs. T0), suggests not only a rapid reduction of the process of miniaturization of the hair but also a transformation of vellus hair into terminal hair. Most interestingly, the efficacy of the NS treatment was evident since T1 and persisted to T6.

3.3. Secondary Endpoints

3.3.1. Pull Test

The hair pull test is used to evaluate the entity of hair loss in the telogen phase. The test helps to gauge the degree of hair loss across the scalp. To ascertain if excess hair loss is present and uniform, the pull test was carried out at each study time in three separate areas of the scalp (upper, frontal, occipital) according to a scale of values from 0 (very high) to 3 (low).
In Table 3, the percentage of improved subjects at T4 versus T0 is summarized. A significant (p < 0.05) difference versus baseline (T0) among both groups was found at the end of the treatment phase (T4). Moreover, at T5 and T6, the difference versus placebo was still present (Table 3), indicative of the long-term effect of NS supplementation. The NS treatment showed a significant increase in tensile strength till T6 (vs. placebo). This result emphasizes, even more, the “reinforcing” activity of the NS supplementation.

3.3.2. Self-Assessment Questionnaire

A higher percentage of subjects who took the NS noted a reduction in daily hair loss, an increase in brightness, and the presence of stronger hair. For the placebo, the efficacy judgment was generally less marked (Figure 1). In particular, for subjects treated with NS compared with placebo, there were significant improvements in hair growth (Holm–Sidak adjusted tests p < 0.05 T1, T2, T3, T4, and T5 vs. placebo) (Figure 1a); hair volume (80% NS vs. 24% placebo at T4; 60% NS vs. 12% placebo at T6) (Figure 1b); hair shine (80% NS vs. 17% placebo at T4; 70% NS vs. 10% placebo at T6) (Figure 1c).

3.3.3. Safety

No side effects related to the study products occurred during the trial and the efficacy and good tolerance of the study products were also confirmed by the volunteers’ judgment.

4. Discussion

The results of the present study highlighted that the supplementation of a novel supplement (NS) containing Ganoderma lucidum, Linum usitatissimum L., Cynara scolymus L., and Galeopsis segetum Neck., a patented composition comprising rutin and PUFAs [7], zinc, biotin, and ornithine, to men and women with telogen effluvium-like phenomena was safe and effective, compared to placebo.
The results showed a significant increase in hair in the anagen phase, hair density, and vellus hair counts from fifteen days of treatment to two months of follow-up, compared to placebo. These improvements were accompanied by significant and progressive improvement in hair tensile strength and hair growth, and volume and brightness increase, as determined by the self-assessment questionnaire. Taking these results together demonstrated a steady improvement from baseline to the end of treatment (90 days) and two months of follow-up (150 days).
TE-like phenomena are very common among men and women. These phenomena are mainly linked to diffuse hair thinning.
The definition of “hair loss” in English-speaking culture now tends to define all the modifications of the bulb cycle, regardless of the specific cause, as a fundamental marker of hair loss. All the phenomena of “hair loss”, in the most modern sense, can be generally defined as “telogen effluvium-like” phenomena.
Several causes have been reported to be responsible for these phenomena, including heredity, comorbidities (e.g., thyroid disease), pregnancy, malnutrition or rapid weight loss, iron deficiency or vitamin D deficiency, or stress [2,3].
Current research is highlighting the nutritional impact on hair growth [18,19]. The cell of the HF is characterized by a fast division and this makes it very sensitive to any nutritional reduction [19]. Therefore, the role of inflammation, oxidative stress, ageing, dihydrotestosterone, and stress has been well documented in hair loss [20,21,22].
The results of the present study demonstrate that nutritional supplementation may be beneficial in TE-like phenomena when there are no associated hormones. Treatment with NS showed positive significant results in all the parameters evaluated in the study, compared to placebo.
The ingredients in the NS supplement provide a unique therapeutic value to its multi-active clinical biological activity versus multiple causative factors of hair thinning in TE-like phenomena.
Triterpenoids isolated from G. lucidum (Fr.) (Reishi) showed a potent inhibitory activity of 5-alpha reductase [9]. This complements the documented effects of another botanical extract, C. scolymus L. leaf extract, which is a rich source of polyphenolic compounds with a strong antioxidant potential [12]. G. segetum Neck. is a herbaceous species belonging to the Lamiaceae family. The plant is present in the BELFRIT list and the lists of the Italian Ministry of Health with the claim: “Well-being of nails and hair” [23]. The botanical extract of this plant has been studied and patented for its antioxidant and inhibitory effect on 5α reductase (isoform 2), which is the main target of the drug finasteride [6,7]. G. segetum extract also stimulates the synthesis of cytokeratin 6A by outer-root sheet (ORS) cells in the HF [6,7].
The NS supplement also contains a patented combination of rutin and PUFAs from L. usitatissimum L., having an inhibitory activity on 5α reductase [24]. L. usitatissimum L. is rich in the PUFAs omega-3 (alpha-linolenic acid) and omega-6 (linoleic acid) that can be useful in counteracting the production of DHT through inhibition of 5α reductase [8,9]. In vivo tests with omega-3, 6 PUFAs were effective in reducing telogen and hair miniaturization [10]. Rutin is a bioflavonoid found in plants (Ruta graveolens L. (Rutaceae), Sophora japonica L. (Fabaceae), etc.) with numerous beneficial activities for human health [13] as an iron chelator that prevents radical reactions and it also possesses antiandrogenic activity [13].
Hair thinning may be improved with vitamin and mineral supplementation which are important for normal cell growth [10]. Zinc, in particular, plays a very important role in HF biology since it is a structural element of hair proteins [14,15,25]. It is also a regulatory factor of numerous enzymatic reactions (cofactor of superoxide dismutase, an antioxidant enzyme that counteracts the action of free radicals and is an inhibitor of 5-alpha reductase) [15].
Biotin, also known as vitamin H, is a coenzyme important for the functioning of various enzymes involved in the metabolism of nutrients, and also for the hair follicle [14].
Considering that the HF has also been shown to be dependent on polyamine synthesis for its growth, function, and cycling [16,26,27,28], the NS formulation also contains, as an essential amino acid, ornithine which is involved in the urea cycle and also in the biosynthesis of polyamines [28]
The NS has also been formulated in patented dosage form, comprising a polymeric matrix containing hyaluronic acid and a non-ionic polymer, to obtain a gradual release in the intestine for optimal absorption of active ingredients [29].

5. Conclusions

This study demonstrated that the supplementation of a novel nutraceutical product (NS) containing active botanicals, a patented composition comprising rutin and polyunsaturated fatty acids (PUFAs), zinc, biotin and ornithine, decreases hair shedding and promotes hair growth in subjects with TE-like phenomena. The supplement was found to be well tolerated by subjects enrolled in the study.
This is just a preliminary study on the efficacy of the supplement under study. Future work will include longer and larger studies.

Author Contributions

Conceptualization, F.R.; Methodology, F.R.; Formal analysis, B.M. and D.P.; Investigation, F.R.; Data curation, D.P.; Writing—original draft, B.M. and D.P.; Writing—review & editing, F.R. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by Giuliani S.p.A.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethical Independent Committee for clinical, not pharmacological, investigation in Genoa (Italy) (protocol code: GIU-SFRP1-0120).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The data presented in this study are available on request from the corresponding author. The data are not publicly available due to protection of patient’s privacy.

Conflicts of Interest

D.P. and B.M. were employed by Giuliani Spa. F.R., serve as consultant for Giuliani SpA.

References

  1. Phillips, T.G.; Slomiany, W.P.; Allison, R. Hair Loss: Common Causes and Treatment. Am. Fam. Physician 2017, 96, 371–378. [Google Scholar] [PubMed]
  2. Sadick, N.S.; Callender, V.D.; Kircik, L.H.; Kogan, S. New Insight Into the Pathophysiology of Hair Loss Trigger a Paradigm Shift in the Treatment Approach. J. Drugs Derm. 2017, 16, s135–s140. [Google Scholar]
  3. Cash, T.F.; Price, V.H.; Savin, R.C. Psychological effects of androgenetic alopecia on women: Comparisons with balding men and with female control subjects. J. Am. Acad. Derm. 1993, 29, 568–575. [Google Scholar] [CrossRef] [PubMed]
  4. Tabolli, S.; Sampogna, F.; di Pietro, C.; Mannooranparampil, T.J.; Ribuffo, M.; Abeni, D. Health status, coping strategies, and alexithymia in subjects with androgenetic alopecia: A questionnaire study. Am. J. Clin. Derm. 2013, 14, 139–145. [Google Scholar] [CrossRef] [PubMed]
  5. Han, S.H.; Byun, J.W.; Lee, W.S.; Kang, H.; Kye, Y.-C.; Kim, K.-H.; Kim, D.-W.; Kim, M.-B.; Kim, S.-J.; Kim, H.O.; et al. Quality of life assessment in male patients with androgenetic alopecia: Result of a prospective, multicenter study. Ann. Derm. 2012, 24, 311–318. [Google Scholar] [CrossRef] [Green Version]
  6. Pinto, D.; Giuliani, G.; Marzani, B. 209 Galeopsis segetum Necker extracts for the prevention and treatment of hair loss. J. Investig. Derm. 2016, 136, S196. [Google Scholar] [CrossRef]
  7. Giammaria, G.; Anna, B.; Barbara, M. Use of a Vegetal Extract for the Prevention and Treatment of Hair Loss. U.S. Patent EP3062636B1, 27 June 2018. [Google Scholar]
  8. Rashed, M.M.; Shallan, M.; Mohamed, D.A.; Fouda, K.; Hanna, L.M. Biological Evaluation of Anti-androgenic Effect of Some Plant Foods. J. Food Nutr. Res. 2015, 2, 645–651. [Google Scholar] [CrossRef] [Green Version]
  9. Liu, J.; Shimizu, K.; Kondo, R. Anti-androgenic activity of fatty acids. Chem. Biodivers. 2009, 6, 503–512. [Google Scholar] [CrossRef]
  10. Le Floc’h, C.; Cheniti, A.; Connétable, S.; Piccardi, N.; Vincenzi, C.; Tosti, A. Effect of a nutritional supplement on hair loss in women. J. Cosmet. Derm. 2015, 14, 76–82. [Google Scholar] [CrossRef]
  11. Benzie, I.F.F.; Wachtel-Galor, S. Herbal Medicine: Biomolecular and Clinical Aspects, 2nd ed.; CRC Press/Taylor & Francis: Boca Raton, FL, USA, 2011. Available online: https://www.ncbi.nlm.nih.gov/books/NBK92771/ (accessed on 28 June 2022).
  12. Wang, M.; Simon, J.E.; Aviles, I.F.; He, K.; Zheng, Q.Y.; Tadmor, Y. Analysis of antioxidative phenolic compounds in artichoke (Cynara scolymus L.). J. Agric. Food Chem. 2003, 51, 601–608. [Google Scholar] [CrossRef]
  13. Jahan, S.; Munir, F.; Razak, S.; Mehboob, A.; Ain, Q.U.; Ullah, H.; Afsar, T.; Shaheen, G.; Almajwal, A. Ameliorative effects of rutin against metabolic, biochemical and hormonal disturbances in polycystic ovary syndrome in rats. J. Ovarian Res. 2016, 9, 86. [Google Scholar] [CrossRef] [PubMed]
  14. Almohanna, H.M.; Ahmed, A.A.; Tsatalis, J.P.; Tosti, A. The Role of Vitamins and Minerals in Hair Loss: A Review. Derm. Ther. 2019, 9, 51–70. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Dhaher, S.A.; Yacoub, A.A.; Jacob, A.A. Estimation of Zinc and Iron Levels in the Serum and Hair of Women with Androgenetic Alopecia: Case-control Study. Indian. J. Derm. 2018, 63, 369–374. [Google Scholar] [CrossRef] [PubMed]
  16. Ramot, Y.; Pietilä, M.; Giuliani, G.; Rinaldi, F.; Alhonen, L.; Paus, R. Polyamines and hair: A couple in search of perfection. Exp. Derm. 2010, 19, 784–790. [Google Scholar] [CrossRef]
  17. Harrison, S.; Bergfeld, W. Diffuse hair loss: Its triggers and management. Clevel. Clin. J. Med. 2009, 76, 361–367. [Google Scholar] [CrossRef] [PubMed]
  18. Finner, A.M. Nutrition and hair: Deficiencies and supplements. Dermatol. Clin. 2013, 31, 167–172. [Google Scholar] [CrossRef]
  19. Piccardi, N.; Manissier, P. Nutrition and nutritional supplementation: Impact on skin health and beauty. Dermatoendocrinol 2009, 1, 271–274. [Google Scholar] [CrossRef] [Green Version]
  20. Peyravian, N.; Deo, S.; Daunert, S.; Jimenez, J.J. The Inflammatory Aspect of Male and Female Pattern Hair Loss. J. Inflamm. Res. 2020, 13, 879–881. [Google Scholar] [CrossRef]
  21. Choi, S.; Zhang, B.; Ma, S.; Gonzalez-Celeiro, M.; Stein, D.; Jin, X.; Kim, S.T.; Kang, Y.L.; Besnard, A.; Rezza, A.; et al. Corticosterone inhibits GAS6 to govern hair follicle stem-cell quiescence. Nature 2021, 592, 428–432. [Google Scholar] [CrossRef]
  22. Breitkopf, T.; Leung, G.; Yu, M.; Wang, E.; McElwee, K.J. The basic science of hair biology: What are the causal mechanisms for the disordered hair follicle? Derm. Clin. 2013, 31, 1–19. [Google Scholar] [CrossRef]
  23. Belfrit List. Available online: https://ec.europa.eu/growth/tools-databases/tris/en/search/?trisaction=search.detail&year=2017&num=276 (accessed on 28 June 2022).
  24. Patent number EP2124922B1 (A2): Composition Comprising Rutin and Polyunsaturated Fatty Acid having an Inhibitory Activity on 5 Alpha-Reductase. Available online: https://xueshu.baidu.com/s?wd=paperuri:(8951b897917cb8e6b2e50c9213c155a3)&filter=sc_long_sign&sc_ks_para=q%3DComposi-tion+comprising+rutin+and+polyunsaturated+fatty+acid+having+an+inhibitory+activity+on+5+%CE%B1-reductase&tn=SE_baiduxueshu_c1gjeupa&ie=utf-8&sc_us=13837088404048465021 (accessed on 28 June 2022).
  25. Naieni, F.F.; Ebrahimi, B.; Vakilian, H.R.; Shahmoradi, Z. Serum iron, zinc, and copper concentration in premature graying of hair. Biol. Trace. Elem. Res. 2012, 146, 30–34. [Google Scholar] [CrossRef] [PubMed]
  26. Pietila, M.; Alhonen, L.; Halmekyto, M.; Kanter, P.; Janne, J.; Porter, C.W. Activation of polyamine catabolism profoundly alters tissue polyamine pools and affects hair growth and female fertility in transgenic mice overexpressing spermidine/spermine N1-acetyltransferase. J. Biol. Chem. 1997, 272, 18746–18751. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Pietila, M.; Parkkinen, J.J.; Alhonen, L.; Janne, J. Relation of skin polyamines to the hairless phenotype in transgenic mice overexpressing spermidine/spermine N-acetyltransferase. J. Invest. Derm. 2001, 116, 801–805. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  28. Soler, A.P.; Gilliard, G.; Megosh, L.C.; O’Brien, T.G. Modulation of murine hair follicle function by alterations in ornithine decarboxylase activity. J. Invest. Derm. 1996, 106, 1108–1113. [Google Scholar] [CrossRef]
  29. Giammaria, G.; Anna, B.; Antonio, M.; Antonio, L. Dosage Forms for Oral Administration of Active Substances. U.S. Patent EP2988782B1, 2 March 2016. [Google Scholar]
Cosmetics 09 00135 g001 550
Figure 1. Percentage of participants with some improvement under items evaluated in both groups after 90 days (T4) and 150 days (T6). (a) hair growth, (b) hair volume and (c) hair shine as evaluated by a self-assessment questionnaire by volunteers (0–10 scale). Asterisks indicate a sig-nificant difference to the control (* p < 0.05).
Figure 1. Percentage of participants with some improvement under items evaluated in both groups after 90 days (T4) and 150 days (T6). (a) hair growth, (b) hair volume and (c) hair shine as evaluated by a self-assessment questionnaire by volunteers (0–10 scale). Asterisks indicate a sig-nificant difference to the control (* p < 0.05).
Cosmetics 09 00135 g001
Table
Table 1. Subjects’ characteristics at baseline.
Table 1. Subjects’ characteristics at baseline.
DemographicNS SupplementPlacebo
Men (n, %)13 (43%)14 (46%)
Women (n, %)17 (57%)16 (54%)
Age (y, mean ± DS)45.9 ± 11.643.3 ± 12.8
NS: nutritional supplement (Bioscalin® NOVA•Genina, Giuliani Spa, Milan, Italy).
Table
Table 2. % increase in the percentage of hair in the anagen phase, the density of hair in the anagen phase (n/cm2), and vellus hair (miniaturized, smaller, and thinner hair).
Table 2. % increase in the percentage of hair in the anagen phase, the density of hair in the anagen phase (n/cm2), and vellus hair (miniaturized, smaller, and thinner hair).
NS SupplementPlacebo
T1T2T3T4T5T6T1T2T3T4T5T6
Anagen Hair *12% a,b24% a,b29% a,b33% a,b28% a,b17% a,b1%4%0%1%0%0%
Hair Density12% a,b22% a,b31% a,b35% a,b33% a,b15% a,b1%5%2%11%2%1%
Vellus Hair−4% a,b−14% a,b−21% a,b−27% a,b−15% a,b−9% a,b0%−1%−3%−6%3% a0%
* % variation versus T0, a Holm–Sidak adjusted p < 0.05 vs. T0, b p < 0.05 vs. placebo.
Table
Table 3. Pull test.
Table 3. Pull test.
NS SupplementPlacebo
T4T5T6T4T5T6
Pull Test *54% a,b42% a,b38% a,b21%22%4%
* % variation versus T0, a Holm–Sidak adjusted p < 0.05 vs. T0, b p < 0.05 vs. placebo.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Rinaldi, F.; Marzani, B.; Pinto, D. Evaluation of Tolerance and Trichological Efficacy of a Food Supplement in Men and Women with Telogen Effluvium-like Disorder. Cosmetics 2022, 9, 135. https://doi.org/10.3390/cosmetics9060135

AMA Style

Rinaldi F, Marzani B, Pinto D. Evaluation of Tolerance and Trichological Efficacy of a Food Supplement in Men and Women with Telogen Effluvium-like Disorder. Cosmetics. 2022; 9(6):135. https://doi.org/10.3390/cosmetics9060135

Chicago/Turabian Style

Rinaldi, Fabio, Barbara Marzani, and Daniela Pinto. 2022. "Evaluation of Tolerance and Trichological Efficacy of a Food Supplement in Men and Women with Telogen Effluvium-like Disorder" Cosmetics 9, no. 6: 135. https://doi.org/10.3390/cosmetics9060135

APA Style

Rinaldi, F., Marzani, B., & Pinto, D. (2022). Evaluation of Tolerance and Trichological Efficacy of a Food Supplement in Men and Women with Telogen Effluvium-like Disorder. Cosmetics, 9(6), 135. https://doi.org/10.3390/cosmetics9060135

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop